Area of research
Nuclear and High Energy Physics
Research interest
Research focused on Oncology and Fibroblast activation protein, with related work in Nomogram, Logistic regression, Environmental health. Notable publications include 'Targeting Carcinoma-Associated Fibroblasts Within the Tumor Stroma With a Fibroblast Activation Protein-Activated Prodrug', 'A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma', and 'Benchmark DEBORA: Assessment of MCFD compared to high-pressure boiling pipe flow measurements'.
A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma
Benchmark DEBORA: Assessment of MCFD compared to high-pressure boiling pipe flow measurements
MA17.07 Durvalumab Plus Anlotinib Versus Durvalumab as Maintenance Treatment in ES-SCLC (DURABLE): A Randomized, Phase 2 Trial
320MO Tibremciclib (BPI-16350) plus fulvestrant in patients with HR+/HER2- advanced breast cancer after progressing on endocrine therapy: A randomized, multicenter, double-blind, phase III study
1759P Long-term updated outcomes of a phase II study of ripretinib vs. sunitinib in chinese patients with advanced gastrointestinal stromal tumor
CT-based radiomics nomogram for the preoperative prediction of microsatellite instability and clinical outcomes in colorectal cancer: a multicentre study
424P Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer: Updated survival results from the phase II PICTURE trial
MA14.05 Tumor Tissue and Plasma EGFR Exon 20 Insertion Mutation Status in NSCLC Patients Treated with Sunvozertinib
[Association of dietary patterns and diabetes risk level among adult residents in Datong city of Shanxi Province].
Targeting Carcinoma-Associated Fibroblasts Within the Tumor Stroma With a Fibroblast Activation Protein-Activated Prodrug